Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial

What Was Tested

This randomized controlled trial paper looks at Glucagon.

Who Took Part

The abstract describes 141 subjects taking part.

By PubMed's age tags, the people studied were teenagers, adults, middle-aged adults and older adults, both men and women.

This investigator-initiated, double-blind, randomized-parallel 20-week study enrolled 141 subjects.

A subset of 85 patients wore blinded continuous glucose monitors (CGM) for 5 separate 7-day periods.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and parallel-group study.

The subjects were allocated by chance, so the Glucagon group and the comparison group should start out alike.

As a double-blind Glucagon study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Glucagon could be set against what happens without it.

The Glucagon group and the comparison group ran side by side rather than switching.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Blood Glucose Self-Monitoring, Diabetes Mellitus, Type 1, Dipeptidyl-Peptidase IV Inhibitors, Glucagon, Glucagon-Like Peptide 1 and Hypoglycemic Agents.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glucagon in 141 subjects.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2013 (Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists), a journal based in United States.

More context: the Glucagon compound page, all human trials.